These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 9213613)

  • 1. The position of intellectual property rights in drug discovery and development from natural products.
    Boyd MR
    J Ethnopharmacol; 1996 Apr; 51(1-3):17-25; discussion 25-7. PubMed ID: 9213613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Juridical and sociocultural problems on the definition of a law concerning property, usage and access to genetic resources in Colombia.
    Calle R
    J Ethnopharmacol; 1996 Apr; 51(1-3):127-42; discussion 142-6. PubMed ID: 9213609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tanzania's policy on biodiversity prospecting and drug discovery programs.
    Mahunnah RL; Mshigeni KE
    J Ethnopharmacol; 1996 Apr; 51(1-3):221-8. PubMed ID: 9213620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Legal issues in sharing the benefits of biodiversity prospecting.
    Mays TD; Mazan KD
    J Ethnopharmacol; 1996 Apr; 51(1-3):93-102; discussion 102-9. PubMed ID: 9213633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interests and policies of the state of Sarawak, Malaysia regarding intellectual property rights for plant derived drugs.
    Chung FJ
    J Ethnopharmacol; 1996 Apr; 51(1-3):201-4. PubMed ID: 9213617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicinal plant genetic resources and international cooperation: the Brazilian perspective.
    Elisabetsky E; Costa-Campos L
    J Ethnopharmacol; 1996 Apr; 51(1-3):111-9; discussion 119-20. PubMed ID: 9213607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The UIC ICBG (University of Illinois at Chicago International Cooperative Biodiversity Group) Memorandum of Agreement: a model of benefit-sharing arrangement in natural products drug discovery and development.
    Soejarto DD; Gyllenhaal C; Fong HH; Xuan LT; Hiep NT; Hung NV; Bich TQ; Southavong B; Sydara K; Pezzuto JM
    J Nat Prod; 2004 Feb; 67(2):294-9. PubMed ID: 14987071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological diversity, indigenous knowledge, drug discovery and intellectual property rights: creating reciprocity and maintaining relationships.
    King SR; Carlson TJ; Moran K
    J Ethnopharmacol; 1996 Apr; 51(1-3):45-57. PubMed ID: 9213630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intellectual property rights in Costa Rica in the light of the Biodiversity Convention].
    Salazar R; Cabrera JA
    J Ethnopharmacol; 1996 Apr; 51(1-3):177-93. PubMed ID: 9213615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Access to affordable HIV/AIDS drugs: the human rights obligations of multinational pharmaceutical corporations.
    Ferreira L
    Fordham Law Rev; 2002 Dec; 71(3):1133-79. PubMed ID: 12523370
    [No Abstract]   [Full Text] [Related]  

  • 11. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
    Chaves GC; Oliveira MA; Hasenclever L; de Melo LM
    Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
    Ghosh S
    Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138
    [No Abstract]   [Full Text] [Related]  

  • 13. Intellectual property rights and traditional medicine: policy dilemmas at the interface.
    Timmermans K
    Soc Sci Med; 2003 Aug; 57(4):745-56. PubMed ID: 12821021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug patents and intellectual property rights.
    Raj GM; Priyadarshini R; Mathaiyan J
    Eur J Clin Pharmacol; 2015 Apr; 71(4):403-9. PubMed ID: 25640303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
    Spectar JM
    Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
    [No Abstract]   [Full Text] [Related]  

  • 16. "Studies on biodiversity of Vietnam and Laos" 1998-2005: examining the impact.
    Soejarto DD; Zhang HJ; Fong HH; Tan GT; Ma CY; Gyllenhaal C; Riley MC; Kadushin MR; Franzblau SG; Bich TQ; Cuong NM; Hiep NT; Loc PK; Xuan le T; Hai NV; Hung NV; Chien NQ; Binh le T; Vu BM; Ly HM; Southavong B; Sydara K; Bouamanivong S; Pezzuto JM; Rose WC; Dietzman GR; Miller BE; Thuy TV
    J Nat Prod; 2006 Mar; 69(3):473-81. PubMed ID: 16562860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical patents and some international trade issues: Canada, the United States, and NAFTA.
    Tancer RS
    Clin Ther; 1993; 15(6):1177-84; discussion 1120. PubMed ID: 8111813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intellectual property. Challenges to India's pharmaceutical patent laws.
    Sampat BN; Shadlen KC; Amin TM
    Science; 2012 Jul; 337(6093):414-5. PubMed ID: 22767892
    [No Abstract]   [Full Text] [Related]  

  • 19. Patenting bioactive molecules from biodiversity: the Brazilian experience.
    Nogueira RC; de Cerqueira HF; Soares MB
    Expert Opin Ther Pat; 2010 Feb; 20(2):145-57. PubMed ID: 20099999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International intellectual property strategies for therapeutic antibodies.
    Storz U
    MAbs; 2011; 3(6):596-606. PubMed ID: 22123063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.